Document Detail

Effects of HbA(1c) and weight reduction on blood pressure in patients with type 2 diabetes mellitus treated with exenatide.
MedLine Citation:
PMID:  22510305     Owner:  NLM     Status:  Publisher    
Aim: Treatment of patients with type 2 diabetes with GLP-1 receptor agonist exenatide has demonstrated improvements in glycemic control coupled with weight loss and lowered blood pressure. We examined the synergy between improved glycemia and weight loss on blood pressure reduction in patients treated with either exenatide twice daily (BID) or once weekly (QW). Methods: Combining data from 3 controlled trials, 686 (53% male) patients (baseline mean±SD: age 55±10 years, weight 95±20 kg, SBP/DBP 130/79 ±15/9 mmHg, HbA(1c) 8.3±1.1%) treated with exenatide QW (n=541) or BID (n=145) were observed over 26 weeks. Using weighted means (WM) of the longitudinal measures of HbA(1c) and weight, patients were subdivided into 4 groups at each visit by glycemic and weight responses; patients who failed to reduce both HbA(1c) and weight below WMs became the reference group (R). The other 3 groups corresponded to patients with HbA(1c) reduction (A), weight reduction (W), and both HbA(1c) and weight reduction (AW). Results: Compared to R, patients in AW, A, and W groups had a significantly higher likelihood of improving SBP <130 mmHg by 88%, 30% and 61% respectively. Compared to R, patients in AW, A, and W had 63%, 13% and 45% higher likelihood of improving DBP <80 mmHg. Conclusion: Although the mechanism of blood pressure lowering effect of exenatide is not established, it appears that the short-term dynamics of blood pressure is related to concomitant effects on glycemia and body weight. These data offer a preliminary insight into the possible cardiometabolic effects of GLP-1 receptor agonism.
S Paul; J Best; K Klein; J Han; D Maggs
Related Documents :
22660685 - Analysis of correlations between n-terminal prohormone of brain natriuretic peptide (nt...
1670745 - The addition of doxazosin to the treatment regimen of patients with hypertension not ad...
322485 - Cardiac performance and beta-adrenergic blockade in arterial hypertension.
6363365 - Effects of physical training on adrenergic sensitivity in obesity.
19751735 - Role of placental growth factor in mesenteric neoangiogenesis in a mouse model of porta...
22660685 - Analysis of correlations between n-terminal prohormone of brain natriuretic peptide (nt...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-4-17
Journal Detail:
Title:  Diabetes, obesity & metabolism     Volume:  -     ISSN:  1463-1326     ISO Abbreviation:  -     Publication Date:  2012 Apr 
Date Detail:
Created Date:  2012-4-18     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100883645     Medline TA:  Diabetes Obes Metab     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
© 2012 Blackwell Publishing Ltd.
Queensland Clinical Trials & Biostatistics Centre, School of Population Health, The University of Queensland, Australia Amylin Pharmaceuticals, Inc., San Diego, California.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Endocannabinoids Modulate Nanc Inhibitory Neurotransmission In Strips From The Mouse Gastric Fundus.
Next Document:  Consequences of oxidative stress in age-related macular degeneration.